Abbott Pays $400 Million Upfront For Reata’s Preclinical AIM Programs
This article was originally published in The Pink Sheet Daily
Executive Summary
Adding on to the two companies’ collaboration around chronic kidney disease candidate bardoxolone, Abbott will pay a record upfront for preclinical assets to co-develop and co-commercialize Reata’s antioxidant inflammation modulators in a variety of disease areas.